UK markets close in 44 minutes

ProQR Therapeutics N.V. (PRQR)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
6.76+0.01 (+0.15%)
At close: 04:00PM EST
6.76 0.00 (0.00%)
After hours: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close6.75
Open6.72
Bid6.66 x 900
Ask7.02 x 1300
Day's range6.41 - 6.81
52-week range4.05 - 9.46
Volume247,556
Avg. volume340,449
Market cap498.287M
Beta (5Y monthly)0.39
PE ratio (TTM)N/A
EPS (TTM)-1.10
Earnings date23 Feb 2022 - 28 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est24.99
  • Globe Newswire

    ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen

    Top-line data now expected to be announced in Q1 2022Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindness LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases today announced that the last patient completed their last vis

  • Globe Newswire

    ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) (“ProQR”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that it has amended its convertible debt financing agreement entered into in 2020 with Kreos Capital (“Kreos”) and Pontifax Medison Debt Financing (“Pontifax”). The amended agreement provides ProQR with access to up to an additional $90 million

  • Globe Newswire

    ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced the first patients dosed in Phase 2/3 Sirius and Celeste clinical trials of investigational RNA therapy QR-421a for people with USH2A mediated retinitis pigmentosa (RP) and Usher syndrome. “Retinitis pigmentosa (RP) and Usher syndrome associated with USH